New to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PT
As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections.
- As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections.
- Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3.
- The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results .
- Phases 2a and 2b confirmed that the drug had success in 25 out of 26 patients, approximately 94% success with no reinfections.